Vy Vu

Ms. Vy Vu

Thai Nguyen National General Hospital, Thái Nguyên, Vietnam
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Meng-Yi BaiMeng-Yi Bai
Meng-Yi Bai
Vy VuVy Vu
Vy Vu
STSung-Ling Tang
Sung-Ling Tang
Truong HungTruong Hung
Truong Hung
Ching-Wei WangChing-Wei Wang
Ching-Wei Wang
WCWING P. CHAN
WING P. CHAN
In recent years, several types of platelet concentrates have been investigated and applied in many fields, particularly in the musculoskeletal system. Platelet-rich fibrin (PRF) is an autologous biomaterial, a second-generation platelet concentrate containing platelets and growth factors in the form of fibrin membranes prepared from the blood of patients without additives. During tissue regeneration, platelet concentrates contain a higher percentage of leukocytes and a flexible fibrin net as a scaffold to improve cell migration in angiogenic, osteogenic, and antibacterial capacities during tissue regeneration. PRF enables the release of molecules over a longer period, which promotes tissue healing and regeneration. The potential of PRF to simulate the physiology and immunology of wound healing is also due to the high concentrations of released growth factors and anti-inflammatory cytokines that stimulate vessel formation, cell proliferation, and differentiation. These products have been used safely in clinical applications because of their autologous origin and minimally invasive nature. We focused on a narrative review of PRF therapy and its effects on musculoskeletal, oral, and maxillofacial surgeries and dermatology. We explored the components leading to the biological activity and the published preclinical and clinical research that supports its application in musculoskeletal therapy. The research generally supports the use of PRF as an adjuvant for various chronic muscle, cartilage, and tendon injuries. Further clinical trials are needed to prove the benefits of utilizing the potential of PRF.

27 June 2024 in Cosmetics
Verified
Journal Article
Open access
PDF file
TDTran Van Duong
Tran Van Duong
Vy VuVy Vu
Vy Vu
Truong HungTruong Hung
Truong Hung
Artificial intelligence (AI) is revolutionizing plastic surgery through its remarkable advancements in various domains such as image analysis, robotic assistance, predictive analytics, and augmented reality. Predictive analytics, powered by AI, harnesses patient data to predict surgical outcomes, minimize risks, and tailor treatment plans, thereby optimizing patient care and safety. Augmented reality and virtual reality technology are also reshaping the cosmetic surgery landscape, providing immersive experiences for preoperative imaging, intraoperative guidance, and advanced skills through simulation. Looking ahead, the future of AI in plastic surgery holds great promise, including personalized medicine, bioprinting of tissues and organs, and continuous learning through iterative improvement algorithms based on real-world surgical experience. However, amid these transformational advances, ethical considerations and regulatory frameworks must evolve to ensure the responsible deployment of AI, protect patient privacy, minimize errors and algorithmic deviation, and uphold standards of fairness and transparency. Our study aims to explore the role of AI in the field of plastic surgery with the potential for the future in mind. In summary, AI is considered a beacon of innovation in plastic surgery, enhancing surgical precision, enhancing patient outcomes, and heralding a future where interventions rely on personalized technology that will redefine the boundaries of aesthetic and regenerative medicine.

1 June 2022 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
THTruong Nguyen Khanh Hung
Truong Nguyen Khanh Hung
Vy VuVy Vu
Vy Vu
NTNguyen Minh Tri
Nguyen Minh Tri
LHLe Ngoc Hoang
Le Ngoc Hoang
LTLe Van Tuan
Le Van Tuan
Jiunn Horng KangJiunn Horng Kang
Jiunn Horng Kang

31 October 2022 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
NDNguyen Tan Dung
Nguyen Tan Dung
NTNgo Huu Thuan
Ngo Huu Thuan
TDTruong Van Dung
Truong Van Dung
LNLe Van Nho
Le Van Nho
NTNguyen Minh Tri
Nguyen Minh Tri
HUU DANG LUONGHUU DANG LUONG
HUU DANG LUONG

15 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Vy VuVy Vu
Vy Vu
MYMelissa Min-Szu Yao
Melissa Min-Szu Yao
Nguyen Quoc Khanh LeNguyen Quoc Khanh Le
Nguyen Quoc Khanh Le
WCWING P. CHAN
WING P. CHAN
Purpose: Given that early identification of breast cancer type allows for less-invasive therapies, we aimed to develop a machine learning model to discriminate between ductal carcinoma in situ (DCIS) and minimally invasive breast cancer (MIBC). Methods: In this retrospective study, the health records of 420 women who underwent biopsies between 2010 and 2020 to confirm breast cancer were collected. A trained XGBoost algorithm was used to classify cancers as either DCIS or MIBC using clinical characteristics, mammographic findings, ultrasonographic findings, and histopathological features. Its performance was measured against other methods using area under the receiver operating characteristic curve (AUC), sensitivity, specificity, accuracy, precision, and F1 score. Results: The model was trained using 357 women and tested using 63 women with an overall 420 patients (mean [standard deviation] age, 57.1 [12.0] years). The model performed well when feature importance was determined, reaching an accuracy of 0.84 (95% confidence interval [CI], 0.76–0.91), an AUC of 0.93 (95% CI, 0.87–0.95), a specificity of 0.75 (95% CI, 0.67–0.83), and a sensitivity of 0.91 (95% CI, 0.76–0.94). Conclusion: The XGBoost model, combining clinical, mammographic, ultrasonographic, and histopathologic findings, can be used to discriminate DCIS from MIBC with an accuracy equivalent to that of experienced radiologists, thereby giving patients the widest range of therapeutic options.

13 September 2024 in Journal of Global Health
Verified
Journal Article
Open access
Vy VuVy Vu
Vy Vu
AYAmy Ming-Fang Yen
Amy Ming-Fang Yen
MYMelissa Min-Szu Yao
Melissa Min-Szu Yao
YCYeun-Chung Chang
Yeun-Chung Chang
HHHsian-He Hsu
Hsian-He Hsu
WCWING P. CHAN
WING P. CHAN
According to the 2022 Cancer Registration Report of the Ministry of Health and Welfare, breast cancer is the most common cancer among women in Taiwan [1].The Taiwan Health Promotion Administration (HPA) has launched the National Breast Cancer Screening Program and offered free breast cancer screenings biennially to women aged 50 to 69 years since January […]